Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Moderna’s Stronger Vaccine AdComm Vote Indicative Of Second Mover Advantage, Not Data Profile

Executive Summary

Moderna’s COVID-19 vaccine got a more solid ‘yes’ vote than Pfizer/BioNTech’s, but committee chair cautions against drawing any comparisons between the products from the different tallies. Last-minute bickering over FDA’s phrasing of voting question complicated meeting but resulted in minimal harm.

You may also be interested in...



The Evolution Of US FDA Advisory Committee Votes On COVID-19 Vaccines

From surprisingly contentious to surprisingly unanimous, VRBPAC's favorable votes have grown from 17 to 21 over the course of three meetings on coronavirus vaccines.

FDA Experts To Convene For March Panel To Discuss Dermal Fillers

The US agency will hold a meeting of its plastic surgery devices panel to discuss risks associated with, and patient preference for, dermal fillers.

We Still Can’t Hear You: 11 Months Into Pandemic, Virtual US FDA Meetings Still Challenging

With J&J’s panel upcoming, it’s worth reflecting on last year’s COVID-19 vaccine advisory committee meetings. Moderna’s went a bit smoother than Pfizer’s, but hiccups still raise questions about whether agency is getting the advice it needs.

Related Content

Topics

Related Companies

UsernamePublicRestriction

Register

PS143493

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel